BTK inhibitors have transformed the lives of many patients with Chronic Lymphocytic Leukemia and other lymphomas. These drugs "exploded" onto the scene in 2013-2014 and have fundamentally changed the way we treat the disease. What many people don't know is how it all happened..

#ESMO2024 Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial by Alessio Amatu - 97% dfs , 85% organ preservation achieved

What is your stance on the ethical dilemma of withdrawing life support for terminally ill cancer patients who are no longer expected to recover? Dr Amol Akhade Nirmal Raut Journal of Geriatric Oncology ISMPO Dr Vikas Asati, Indore, Medical Oncologist Young Oncologists Group India🇮🇳

Quiz on breast cancer awareness. For individuals to take action in promoting breast health. Early detection saves lives.

Pleasure listening to Dr. Antonio Giuliano, Plenary @ SGBCC2025 - Z011 trial evaluated the necessity of ALND in T1-2 invasive BC and 1-2 positive SLN undergoing lumpectomy + WBRT, found no significant difference in 10-year OS, DFS, LRRFS. Real practice change for Breast Surgery !

Time taken by various drugs to move from MBC to EBC . Pembrolizumab took it 3 years . How much time trastuzumab deruxtecan will take ? Slide by G Curigliano MD PhD #SGBCC2025 OncoAlert Oncology Brothers Yakup Ergün Sara Tolaney Erika Hamilton, MD, FASCO

"Circulating Tumor Cells (CTCs) are a game-changer in breast cancer detection! These cells, shed by tumors into the bloodstream, offer a non-invasive 'liquid biopsy' to monitor cancer progression and treatment response. currently use in clinical trial setting only.

ctDNA is emerging as a promising surrogate marker in breast cancer research. It offers a non-invasive way to monitor disease progression, treatment response, and recurrence risk. SGBCC

Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial 💥In this trial involving clinically node-negative, T1 (90%) or T2 breast cancer patients, omitting surgical axillary staging was noninferior to SLNB after 6 years of follow-up. nejm.org/doi/full/10.10…

How to select older patients with EBC for chemotherapy. Useful tools for clinical practice. SGBCC

Universal testing for BRCA 1 BRCa2 and PALB2 all BC cases. Knowing the mutation translates to better outcomes.

Crazy how fast pathologists have to stay on top of updates! Just this week—HER2 expression guidelines were updated and presented at #USCAP2025. Never a dull moment! #Pathology

Our prayers are with our forces… One nation…Together we Stand

📢 ASCENT-03 delivers for Trodelvy in 1L mTNBC! ❤ Trodelvy (sacituzumab govitecan) shows a statistically significant & clinically meaningful PFS benefit vs chemo ❌ In a tough group: PD-L1–negative or IO-ineligible mTNBC 🧬 First ADC to potentially become 1L backbone for

Cancer is rising in India with 1.4M new cases yearly. Early screening for breast, cervical, oral cancers saves lives. Join NPCDCS, NGOs & campaigns for accessible tests. Spread awareness! #CancerScreeningIndia #EarlyDetectionSavesLives #FightCancer instagram.com/share/_heiSAnlk

#ASCO25 INAVO120: Inavo + palbo + fulvestrant in 1L PIK3CA-mutant HR+/HER2– aBC OS ➡️ 34.0 vs 27.0 mo✅️ PFS ➡️ 17.2 vs 7.3 mo TTC ➡️ 35.6 vs 12.6 mo Hyperglycemia (any) ➡️ 63.4% vs 13.5% Clear OS benefit & ~2y chemo delay—an important advance in endocrine-resistant HR+ aBC

Revolutionizing neuro-oncology! Targeted therapies are bringing precise treatments for CNS tumors. New advances in IDH-mutant gliomas are showing great promise, despite challenges like the blood-brain barrier. #NeuroOncology #BrainTumorResearch ascopubs.org/doi/pdf/10.120…

Carcinoma of Unknown Primary: Cancer without a past 🧬 Early dissemination 🛡️Immune editing of the primary 🧪CK20+, CDX2+, SATB2+ → treat colon-like 🧭Let biology, not anatomy, guide therapy Not a diagnostic failure — a metastatic strategy. nejm.org/doi/full/10.10… #ASCO25

Great talk by Vanita Noronha, MBBS MD DM at #ASCO25 . Nice slide for take home message and limitations of 3 studies and presented post EGFR progression. Most important is LMIC perspective. 👍 Tata Memorial Hospital OncoAlert Alfredo Addeo MD

This is a slide by Dr Sarah Sammons from Dana-Farber that I have referred to heavily in my own clinical practice with my patients whenever we are discussing adjuvant CDK 4/6i